THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE
Health and Medicine Division
Board on Population Health and Public Health Practice
Committee to Review Long-Term Health Effects of Antimalarial Drugs
*****
Congressional Briefings
Mon, Feb 24, 2020
825A Hart Senate Office Bldg. – 11:30 a.m.
and
Mon, Feb 24, 2020
412 Russell Senate Office Bldg. – 3:45 p.m.
and
Mon, Feb 24, 2020
3480 O’Neill House Office Bldg. – 4:00 p.m.
on
Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis
This new report, from the National Academies of Sciences, Engineering, and Medicine, assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by the Department of Defense in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.
These briefings were for members of Congress and congressional staff only. The report was publicly released on February 25, 2020 and can be found, in its entirety, on the Web site of the National Academies Press.